Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02546440
Other study ID # EudraCT-Number: 2014-000924-11
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 2015
Est. completion date September 2022

Study information

Verified date March 2023
Source Universitätsmedizin Mannheim
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective of the trial is to investigate whether oral treatment of patients suffering from cutaneous T cell lymphoma with dimethylfumarate is leading to a significant improvement of modified severity assessment tool (mSWAT) values in the skin after 24 weeks of treatment (primary endpoint). Secondary endpoints are dermatologic life quality index, itching and pain measured by a NRS and the blood involvement if applicable. Primary: safety and efficacy of DMF treatment in CTCL Secondary: Dermatologic Life Quality index, NRS for itching and pain, blood involvement if appl.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date September 2022
Est. primary completion date September 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - Histopathologically confirmed Mycosis fungoides or Sézary syndrome (CTCL stage = Ib according to EORTC-ISCL consensus classification) at study entry with progressive, persistant or recurrent disease - Pretreatment with at least one topical or systemic CTCL therapy or UV therapy, if the prior therapy is not possible anymore or if there is new contraindication or unsatisfactory response - Karnofsky index =70 % (according to Karnofsky DA, Burchenal JH. (1949). "The Clinical Evaluation of Chemotherapeutic Agents in Cancer." In: MacLeod CM (Ed), Evaluation of Chemotherapeutic Agents. Columbia Univ Press. Page 196) - Life expectancy > 3 months - Age = 18 years - Adequate organ function: - differential blood count: hemoglobin = 10 g/dl without transfusions, leukocyte count > 3000/µl, lymphocyte count > 700/µl - liver enzymes = 2 x upper limit of normal (ULN) - serum creatinine = 1.5 mg/dl or calculate creatinine clearance = 50 ml/min, - Negative Pregnancy test from blood, agreement for efficient contraception in male and female patients unless infertility is documented (DMF is not approved during pregnancy) - Ability to understand character and individual consequences of the clinical trial and to provide written informed consent to participate in the study - written informed consent must be given according to ICH/GCP, and national/local regulations, before patient registration and prior to any study specific procedures. Exclusion criteria: - Another active malignant disease with the following exceptions: - Basal or squamous cell carcinoma of the skin - In situ carcinoma of the cervix or the skin - Topical chemotherapy, superficial radiotherapy, photopheresis or systemic CTCL treatment within 28 days before study therapy initiation - Severe systemic disease or infection at study therapy initiation - Prior treatment with DMF or simultaneous topical DMF treatment - Contraindications for treatment with DMF (known hypersensibility to the drug, severe gastrointestinal disease (like ulcerations), Alcohol abuse, other obligately liver- or nephrotoxic medication, known clinically apparent renal or hepatic insufficiency) - Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial - Participation in other clinical studies within 14 days before study therapy initiation - Pregnant or lactating patients

Study Design


Intervention

Drug:
Dimethyl fumarate
dose escalation from 30 mg/d to maximally 720 mg/d over 9 weeks, then continuing with the highest tolerated dose following a preset design in psoriasis treatment in Germany, oral medication in tablet form. Treatment will last 24 weeks or until either progression or unacceptable side effects occur

Locations

Country Name City State
Germany University Medical Center Mannheim

Sponsors (7)

Lead Sponsor Collaborator
Universitätsmedizin Mannheim KKS Netzwerk, Klinikum Krefeld, Klinikum Ludwigshafen, Klinikum Minden, Universitätsklinikum Kiel, Wuerzburg University Hospital

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary safety (via occurrence of AE/SAE) of DMF treatment in CTCL Number of patients with Treatment-related Adverse Events as assessed by CTCAE v4.0 every 2 weeks until 24 weeks of treatment are finished
Primary efficacy (via improvement of Skin involvement measured by the standardized modified severity weighted assessment tool (mSWAT))of DMF treatment in CTCL Changes in the mSWAT scores range from 0 [no patches, Plaques or tumors on the Skin ] to 400 [complete Body covered by Tumors] every 2 weeks until 24 weeks of treatment are finished
Secondary changes in dermatologic life quality index Scores range from 0 [no restriction of life Quality] to 30 [maximal restriction of life Quality] every 2 weeks until 24 weeks of treatment are finished
Secondary changes in pruritus intensity measured by a visual analog scale Scores range from 0 [no Pruritus] to 10 [worst possible Pruritus] every 2 weeks until 24 weeks of treatment are finished
Secondary changes in blood involvement measured by Sezary cell count (if applicable, only in stage IV patients) every 2 weeks until 24 weeks of treatment are finished
See also
  Status Clinical Trial Phase
Recruiting NCT04014374 - Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
Recruiting NCT03340155 - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases N/A
Active, not recruiting NCT01460914 - Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment
Completed NCT04955340 - A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat Phase 1
Recruiting NCT02539472 - Early Diagnosis of Mycosis Fungoides N/A
Recruiting NCT06436677 - A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
Recruiting NCT05680558 - Photopheresis in Early-stage Mycosis Fungoides Phase 2
Recruiting NCT01132989 - Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma Phase 2
Recruiting NCT05414500 - Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides Phase 1
Terminated NCT01663571 - STAT3 in T Cells: At The Crossroads of Inflammation and Cancer
Active, not recruiting NCT02192021 - Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) Phase 1
Recruiting NCT05781386 - A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors Phase 1
Active, not recruiting NCT02576496 - Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Phase 1
Active, not recruiting NCT03775525 - Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer Phase 1
Withdrawn NCT03235869 - Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma Early Phase 1
Active, not recruiting NCT01396070 - Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level N/A
Completed NCT01198665 - RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Phase 1/Phase 2
Recruiting NCT03932279 - Characterization of the Microbiome in Cutaneous T Cell Lymphoma
Not yet recruiting NCT05728879 - Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution Early Phase 1
Not yet recruiting NCT06113081 - Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma